Article Text

Download PDFPDF
Reply: ‘More viral mutants, less HBsAg clearance? One size may not fit all'

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors contributed equally to this letter.

  • Funding Gilead Sciences.

  • Competing interests PR and SL have received grant/research support from Gilead Sciences; SL is an advisor for Gilead Sciences and Bristol-Myers Squibb (BMS); AT is an advisor for and has received grant/research support from Merck, Janssen/Tibotec, Gilead Sciences and Roche and speaker's fees from Merck, Roche and BMS. PR is currently in receipt of a Royal Melbourne Hospital Keir Research Fellowship.

  • Patient consent Obtained.

  • Ethics approval Gilead Sciences.

  • Provenance and peer review Not commissioned; internally peer reviewed.